Antimalarial Drugs Innovators and Market Growth
- Novartis AG
- Sanofi
- Cipla Ltd.
- Ipca Laboratories Ltd.
- GlaxoSmithKline
- Sun Pharmaceutical Industries Ltd.
- Lupin Limited
- Zydus Lifesciences
- Glenmark Pharmaceuticals
- Ajanta Pharma Ltd.
- F. Hoffmann-La Roche Ltd.
- Macleods Pharmaceuticals Ltd.
- Mylan/Viatris
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals
- Strides Pharma Science Ltd.
- Hetero Drugs Ltd.
- Dr. Reddy’s Laboratories
- Alkem Laboratories Ltd.
Market Growth
The global antimalarial drugs market size is calculated at US$ 1.07 in 2024, grew to US$ 1.12 billion in 2025, and is projected to reach around US$ 1.67 billion by 2034. The market is expanding at a CAGR of 4.57% between 2025 and 2034.
What are the Key Trends in the Antimalarial Drugs Market?
- In 2025, the market is experiencing significant expansion due to the accelerating R&D efforts, rising awareness regarding malaria and its treatments, and widespread contribution of strategic collaborations.
- In August 2025, ICMR developed a novel advanced recombinant multi-stage malaria vaccine named Adfalsvax, targeting multiple stages of the malaria parasite's life cycle using genetic technology.
- In May 2025, African health leaders and global partners collaborated to confront the increasing threat of antimalarial drug resistance.
- In August 2024, Aurigene Pharmaceutical Services, the CRDMO arm of India-based Dr. Reddy’s, signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, a US-based company with a proprietary platform for the development and commercialization of cost-effective anti-malarial drugs in the US, Europe, and in low and middle-income countries.
The Antimalarial Drugs Market Value Chain Analysis
R&D
In this sector, with the emergence of investment and participation of scientific research personnel discovery of new candidates, their further developments are being catered to. This also expands the study of drug resistance and optimizing treatment efficacy.
Key Players: Novartis AG, Cipla, Fosun Pharma, Medicines for Malaria Venture (MMV), and Drugs for Neglected Diseases initiative (DNDi), etc.
Distribution to Hospitals, Pharmacies
This usually occurs through the developed supply chains, in which hospitals often receive drugs from respective regional stores and pharmacies acquire from different sources, such as wholesalers or direct suppliers.
Key Players: Max Healthcare, Hiranandani Hospital, IndiaMART, Unicure Remedies Pvt Ltd, and Skymax Life Science Pvt Ltd, etc.
Patient Support and Services
Across the globe, different campaigns are making efforts to educate people regarding malaria symptoms, prevention, and medications. Alongside, through the programs they are distributing insecticide-treated bed nets, offering intermittent preventive treatment for pregnant women, or educating communities to reduce mosquito breeding.
Key Players: Seasonal Malaria Chemoprevention (SMC), Mass Drug Administration (MDA), PAHO, NIH, etc.
Latest Announcements by Industry Leaders
- In August 2025, under the leadership of the Ministry of Health and Public Hygiene, and with the support of Gavi, the Vaccine Alliance, the World Health Organization (WHO), UNICEF, and PATH, Guinea announced the malaria vaccine into its Expanded Programme on Immunization (EPI). Dr. Oumar Diouhé Bah, Minister of Health and Public Hygiene, commented that this step will empower the health system by protecting their population throughout the country in the long term.
- In April 2025, the Pan American Health Organization (PAHO) and CAF Development Bank of Latin America and the Caribbean (CAF) announced a Memorandum of Understanding to expand malaria control activities in the Amazon border regions of countries of the Americas. PAHO Director Dr. Jarbas Barbosa replied that this will support in tackling malaria at the regional level and enhancing the objectives of the Disease Elimination Initiative.
What are the Recent Developments in the Antimalarial Drugs Market?
- In August 2025, South Sudan launched the second phase of R21 malaria vaccine introduction in 52 counties to protect children.
- In July 2024, GSK and Medicines for Malaria Venture (MMV) unveiled a newer single-dose medicine, tafenoquine, to mitigate the relapse of Plasmodium vivax (P. vivax) malaria in malaria-endemic countries Brazil and Thailand.
- In October 2024, AMIVAS Ireland Ltd (AMIVAS), a biopharmaceutical company, launched its Artesunate AMIVAS in Europe and the U.K.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
